NASDAQ · SLGL
Healthcare · Biotechnology
$69.18
Down-$2.39 (-3.45%)
Updated Sep 10, 2026, 8:51 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SLGL closed at $69.18 after 20 trading sessions, down 3.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $70.99 | $70.99 | $68.42 | $69.18 | 47.71K |
| Sep 8, 2026 | $69.06 | $70.20 | $67.79 | $69.37 | 38.59K |
| Sep 4, 2026 | $70.17 | $70.80 | $68.385 | $69.52 | 29.63K |
| Sep 3, 2026 | $71.33 | $72.99 | $69.84 | $70.10 | 58.07K |
| Sep 2, 2026 | $69.48 | $72.09 | $68.00 | $70.43 | 97.7K |
| Sep 1, 2026 | $70.26 | $72.76 | $69.02 | $69.52 | 130.16K |
| Aug 31, 2026 | $67.77 | $70.93 | $66.75 | $69.10 | 111.45K |
| Aug 28, 2026 | $72.61 | $76.00 | $66.15 | $68.81 | 147.79K |
| Aug 27, 2026 | $80.45 | $80.70 | $71.97 | $72.57 | 58.81K |
| Aug 26, 2026 | $81.20 | $81.80 | $77.22 | $79.43 | 68.61K |
| Aug 25, 2026 | $78.88 | $82.19 | $78.88 | $81.72 | 56K |
| Aug 24, 2026 | $76.99 | $78.41 | $75.38 | $77.39 | 59.8K |
| Aug 21, 2026 | $81.92 | $81.92 | $77.17 | $77.73 | 33.32K |
| Aug 20, 2026 | $78.47 | $81.00 | $76.87 | $78.495 | 28.6K |
| Aug 19, 2026 | $79.45 | $83.2099 | $78.59 | $78.59 | 33.33K |
| Aug 18, 2026 | $82.93 | $83.60 | $79.33 | $79.33 | 35.58K |
| Aug 17, 2026 | $85.16 | $90.50 | $81.05 | $83.01 | 109.95K |
| Aug 14, 2026 | $83.69 | $90.79 | $83.69 | $84.69 | 79.4K |
| Aug 13, 2026 | $71.85 | $84.60 | $71.80 | $84.04 | 77.88K |
| Aug 12, 2026 | $80.405 | $80.405 | $70.81 | $71.50 | 52.3K |
The latest Smart Investors Daily articles mentioning SLGL.
SLGL research
Company profile and research snapshot.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 24, 2026 | Mizuho | Outperform | — |
| Jan 20, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 22, 2025 | HC Wainwright & Co. | Buy | — |
| Oct 27, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 20, 2026
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(2.31) by 51.08 percent. This is a 127.1 percent decrease over earnings of $4.17 per share
Benzinga · Jul 20, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $110 price target.
Benzinga · Jun 24, 2026
Wall Street analysts changed outlook on top names, see all changes on Benzinga's analyst ratings page. Check out views on BB, SLGL, PRCT, OGE, TTWO.
Benzinga · Jun 24, 2026
Mizuho analyst Uy Ear initiates coverage on Sol-Gel Technologies (NASDAQ:SLGL) with a Outperform rating and announces Price Target of $285.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLGL.
